Lilly signs $1.3 billion deal with Superluminal to discover obesity medicines using AI – Reuters

  1. Lilly signs $1.3 billion deal with Superluminal to discover obesity medicines using AI  Reuters
  2. Eli Lilly seeks more GPCR weight loss drugs in $1.3bn research deal  Pharmaceutical Technology
  3. Lilly invests in Boston biotech for $1.3B obesity drug deal  The Business Journals
  4. Lilly, Superluminal ink $1.3B pact targeting hard-to-crack GPCRs  FirstWord Pharma
  5. Superluminal Medicines Announces Collaboration with Eli Lilly and Company to Advance Small Molecule Therapeutics for Cardiometabolic Diseases and Obesity  WV News

Continue Reading